Drug Information

Drug General Information
Drug ID
D08PCR
Former ID
DIB001992
Drug Name
CM3.1-AC100
Synonyms
CM-3, CellMed/AstraZeneca; GLP-1 analog (diabetes), CellMed/AstraZeneca
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Phase 1 [523118]
Company
CellMed AG
Target and Pathway
Target(s) Glucagon-like peptide 1 receptor Target Info Agonist [543638]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Reactome Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 523118ClinicalTrials.gov (NCT01165502) Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers. U.S. National Institutes of Health.
Ref 543638(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.